OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor ...
Q1 2026
May 5, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 12, 2025